{"title":"创新型硅胶延伸器在缝合加固或皮肤牵引中的有效性和安全性:一项回顾性研究。","authors":"Anne-Laure Yailian, Emmanuelle Carré, Catherine Rioufol, Luc Thomas, Olivier Beatrix","doi":"10.12968/jowc.2021.0137","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Multiple techniques are available for closing skin defects, such as skin grafts, flaps and tissue expansion. The tissue extender MID SEW (MID, France) was developed to achieve dermatotraction or suture reinforcement. The aim of this study was to evaluate the effectiveness and safety of this innovative silicone extender for large surgical wounds.</p><p><strong>Method: </strong>A single-centre retrospective and observational study on an unselected consecutive cohort of patients treated with a tissue extender was conducted. Indications, initial and final wound surfaces, and adverse events (AEs) were retrieved from electronic medical records. The main outcome measure was the time to complete wound closure.</p><p><strong>Results: </strong>We identified 50 patients from July 2017 to December 2018. Patients underwent cutaneous tumour-wide excision (n=44), or pilonidal disease surgical treatment (n=6). The average initial wound area was 53.3±42.4cm<sup>2</sup>. Healing was complete, without secondary dehiscence, within the first seven days after device withdrawal for 41 patients (82%). At least one AE was experienced by eight patients (16%) during the study period: five inflammation; five wound dehiscence; two skin necrosis; and one pain.</p><p><strong>Conclusion: </strong>This case series suggests that the tissue extender may be effective and safe in its dermatotraction and suture reinforcement indications in the treatment of large wounds after wide excision of skin cancer or treatment of pilonidal disease.</p><p><strong>Declaration of interest: </strong>This work was supported in part by the Hospices Civils de Lyon, France and in part by the University Claude Bernard Lyon 1, France. OB co-owns the patent on the MID SEW system. The authors have no other conflicts of interest to declare.</p>","PeriodicalId":17590,"journal":{"name":"Journal of wound care","volume":"33 7","pages":"533"},"PeriodicalIF":1.5000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effectiveness and safety of an innovative silicone extender in suture reinforcement or dermatotraction: a retrospective study.\",\"authors\":\"Anne-Laure Yailian, Emmanuelle Carré, Catherine Rioufol, Luc Thomas, Olivier Beatrix\",\"doi\":\"10.12968/jowc.2021.0137\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Multiple techniques are available for closing skin defects, such as skin grafts, flaps and tissue expansion. The tissue extender MID SEW (MID, France) was developed to achieve dermatotraction or suture reinforcement. The aim of this study was to evaluate the effectiveness and safety of this innovative silicone extender for large surgical wounds.</p><p><strong>Method: </strong>A single-centre retrospective and observational study on an unselected consecutive cohort of patients treated with a tissue extender was conducted. Indications, initial and final wound surfaces, and adverse events (AEs) were retrieved from electronic medical records. The main outcome measure was the time to complete wound closure.</p><p><strong>Results: </strong>We identified 50 patients from July 2017 to December 2018. Patients underwent cutaneous tumour-wide excision (n=44), or pilonidal disease surgical treatment (n=6). The average initial wound area was 53.3±42.4cm<sup>2</sup>. Healing was complete, without secondary dehiscence, within the first seven days after device withdrawal for 41 patients (82%). At least one AE was experienced by eight patients (16%) during the study period: five inflammation; five wound dehiscence; two skin necrosis; and one pain.</p><p><strong>Conclusion: </strong>This case series suggests that the tissue extender may be effective and safe in its dermatotraction and suture reinforcement indications in the treatment of large wounds after wide excision of skin cancer or treatment of pilonidal disease.</p><p><strong>Declaration of interest: </strong>This work was supported in part by the Hospices Civils de Lyon, France and in part by the University Claude Bernard Lyon 1, France. OB co-owns the patent on the MID SEW system. The authors have no other conflicts of interest to declare.</p>\",\"PeriodicalId\":17590,\"journal\":{\"name\":\"Journal of wound care\",\"volume\":\"33 7\",\"pages\":\"533\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-07-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of wound care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.12968/jowc.2021.0137\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of wound care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12968/jowc.2021.0137","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:目前有多种技术可用于关闭皮肤缺损,如植皮、皮瓣和组织扩张。组织扩张器 MID SEW(法国 MID 公司)是为实现皮肤牵引或缝合加固而开发的。本研究旨在评估这种创新型硅胶扩展器在大面积手术伤口中的有效性和安全性:方法:对使用组织扩展器进行治疗的未经选择的连续患者群进行了一项单中心回顾性观察研究。从电子病历中检索了适应症、初始和最终伤口表面以及不良事件(AEs)。主要结果指标是伤口完全闭合的时间:2017年7月至2018年12月,我们确定了50名患者。患者接受了皮肤肿瘤全切术(n=44)或朝天鼻病手术治疗(n=6)。平均初始伤口面积为(53.3±42.4)平方厘米。41 名患者(82%)的伤口在撤除装置后的头七天内完全愈合,没有继发性开裂。在研究期间,8 名患者(16%)至少出现了一次 AE:5 次发炎;5 次伤口开裂;2 次皮肤坏死;1 次疼痛:本系列病例表明,在治疗皮肤癌广泛切除术后的大面积伤口或治疗朝天鼻病时,组织扩展器在其皮肤牵引和缝合加固适应症方面可能是有效和安全的:本研究部分由法国里昂平民医院(Hospices Civils de Lyon)和法国里昂第一大学(University Claude Bernard Lyon 1)资助。OB 共同拥有 MID SEW 系统的专利。作者没有其他利益冲突需要声明。
Effectiveness and safety of an innovative silicone extender in suture reinforcement or dermatotraction: a retrospective study.
Objective: Multiple techniques are available for closing skin defects, such as skin grafts, flaps and tissue expansion. The tissue extender MID SEW (MID, France) was developed to achieve dermatotraction or suture reinforcement. The aim of this study was to evaluate the effectiveness and safety of this innovative silicone extender for large surgical wounds.
Method: A single-centre retrospective and observational study on an unselected consecutive cohort of patients treated with a tissue extender was conducted. Indications, initial and final wound surfaces, and adverse events (AEs) were retrieved from electronic medical records. The main outcome measure was the time to complete wound closure.
Results: We identified 50 patients from July 2017 to December 2018. Patients underwent cutaneous tumour-wide excision (n=44), or pilonidal disease surgical treatment (n=6). The average initial wound area was 53.3±42.4cm2. Healing was complete, without secondary dehiscence, within the first seven days after device withdrawal for 41 patients (82%). At least one AE was experienced by eight patients (16%) during the study period: five inflammation; five wound dehiscence; two skin necrosis; and one pain.
Conclusion: This case series suggests that the tissue extender may be effective and safe in its dermatotraction and suture reinforcement indications in the treatment of large wounds after wide excision of skin cancer or treatment of pilonidal disease.
Declaration of interest: This work was supported in part by the Hospices Civils de Lyon, France and in part by the University Claude Bernard Lyon 1, France. OB co-owns the patent on the MID SEW system. The authors have no other conflicts of interest to declare.
期刊介绍:
Journal of Wound Care (JWC) is the definitive wound-care journal and the leading source of up-to-date research and clinical information on everything related to tissue viability. The journal was first launched in 1992 and aimed at catering to the needs of the multidisciplinary team. Published monthly, the journal’s international audience includes nurses, doctors and researchers specialising in wound management and tissue viability, as well as generalists wishing to enhance their practice.
In addition to cutting edge and state-of-the-art research and practice articles, JWC also covers topics related to wound-care management, education and novel therapies, as well as JWC cases supplements, a supplement dedicated solely to case reports and case series in wound care. All articles are rigorously peer-reviewed by a panel of international experts, comprised of clinicians, nurses and researchers.
Specifically, JWC publishes:
High quality evidence on all aspects of wound care, including leg ulcers, pressure ulcers, the diabetic foot, burns, surgical wounds, wound infection and more
The latest developments and innovations in wound care through both preclinical and preliminary clinical trials of potential new treatments worldwide
In-depth prospective studies of new treatment applications, as well as high-level research evidence on existing treatments
Clinical case studies providing information on how to deal with complex wounds
Comprehensive literature reviews on current concepts and practice, including cost-effectiveness
Updates on the activities of wound care societies around the world.